Phase III APHINITY Study

Phase III APHINITY Study showed a statistically significant improvement in invasive disease-free survival (iDFS) for people with HER2-positive early breast cancer (EBC) compared to Herceptin and chemotherapy alone

www.gene.com/media/press-releases/14655/2017-03-01/phase-iii-aphinity-study-shows-genentech

More News